中国普外基础与临床杂志

中国普外基础与临床杂志

PD-L1 和 A2aR 在结直肠癌组织中的表达及其临床意义

查看全文

目的 检测结直肠癌组织及其对应的癌旁组织中细胞程式死亡配体 1(PD-L1)和腺苷 2a 受体(A2aR)的蛋白表达并探讨其与结直肠癌患者临床病理学特征的关系。 方法 收集 2013 年 8 月至 2015 年 8 月期间于徐州医科大学附属医院行手术治疗的 106 例结直肠癌患者的癌组织及其对应的癌旁组织石蜡标本,采用免疫组织化学 SP 染色方法检测其中 PD-L1 和 A2aR 蛋白的表达情况。 结果 A2aR 和 PD-L1 蛋白表达阳性率在结直肠癌组织中均分别明显高于其在对应的癌旁组织[A2aR:74(69.8%)比 35(33.0%),χ2=28.721,P<0.001;PD-L1:57(53.8%)比 28(26.4%),χ2=16.516,P<0.001]。结直肠癌组织中 A2aR 和 PD-L1 蛋白阳性表达均与结直肠癌患者的分化程度(A2aR:χ2=9.198,P=0.010;PD-L1:χ2=8.354,P=0.015)、浸润深度(A2aR:χ2=6.737,P=0.009;PD-L1:χ2=6.437,P=0.011)及 TNM 分期(A2aR:χ2=4.884,P=0.027;PD-L1:χ2=8.246,P=0.004)有关,且 A2aR 蛋白阳性表达还与肿瘤直径(χ2=4.386,P=0.036)和 CEA 阳性(χ2=6.315,P=0.012)有关而 PD-L1 蛋白阳性表达与此无关(P>0.05);A2aR 和 PD-L1 蛋白阳性表达均与结直肠癌患者的性别、年龄、肿瘤部位、有无淋巴结转移及 CA19-9 无关(P>0.05)。PD-L1 与 A2aR 蛋白表达在结直肠癌组织中呈正相关(rs=0.237,P=0.027)。 结论 PD-L1 和 A2aR 蛋白在结直肠癌组织中表达阳性率均较高提示其表达可能与结直肠癌恶性进展程度有关。

Objective To detect expressions of programmed cell death ligand 1 (PD-L1) and adenosine 2a receptor (A2aR) proteins in colorectal cancer tissues and investigate its relationship with clinicopathologic features. Methods The colorectal cancer tissues and corresponding paracancerous tissue of 106 patients with colorectal cancer were collected, the patients underwent surgery in the Affiliated Hospital of Xuzhou Medical University from August 2013 to August 2015. The immunohistochemical staining was used to detect the expressions of A2aR and PD-L1 proteins. Results The positive rates of A2aR and PD-L1 protein expression in the colorectal cancer tissues were significantly higher than those in the corresponding paracancerous tissues, respectively (A2aR: 74(69.8%) versus 35(33.0%), χ2=28.721, P<0.001; PD-L1, 57(53.8%)versus 28(26.4%), χ2=16.516, P<0.001), which in the colorectal cancer tissues were correlated with the differentiation degree (A2aR:χ2=9.198, P=0.010; PD-L1: χ2=8.354, P=0.015), infiltration depth (A2aR: χ2=6.737, P=0.009; PD-L1: χ2=6.437, P=0.011), and TNM staging (A2aR: χ2=4.884, P=0.027; PD-L1: χ2=8.246, P=0.004) and were not correlated with the gender, age, tumor portion, lymph node metastasis and CA19-9 (P>0.05), but the positive rate of A2aR protein expression was correlated with the differentiation degree (χ2=4.386, P=0.036) and CEA positive (χ2=6.315, P=0.012) and the positive rate of PD-L1 protein expression was not correlated with it (P>0.05). The expression of PD-L1 protein was positively correlated with the expression of A2aR in colorectal cancer tissues (rs=0.237, P=0.027). Conclusion PD-L1 and A2aR protein expressions are higher in colorectal cancer tissues, it is provide that both of them might play an important role in promoting occurrence and development of colorectal cancer.

关键词: 结直肠癌; 细胞程式死亡配体 1; 腺苷 2a 受体

Key words: colorectal cancer; programmed cell death ligand 1; adenosine 2a receptor

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov, 2015, 14(8): 561-584.
2. Bertucci F, Finetti P, Colpaert C, et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, 2015, 6(15): 13506-13519.
3. Tkachev V, Goodell S, Opipari AW, et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol, 2015, 194(12): 5789-5800.
4. Leone RD, Lo YC, Powell JD. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J, 2015, 13: 265-272.
5. Hatfield SM, Sitkovsky M. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer. Curr Opin Pharmacol, 2016, 29: 90-96.
6. 柴立勋, 孙克林, 郭黎平. 食管鳞癌中 Ezrin 和 CD44-v6 的表达及其临床意义. 中华肿瘤杂志, 2007, 29(9): 685-688.
7. Mu CY, Huang JA, Chen Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol, 2011, 28(3): 682-688.
8. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol, 2017, 8: 561.
9. 吕学文, 徐琼, 陈焕伟, 等. PD-1、PD-L1 蛋白在外周 T 细胞淋巴瘤中的表达及其与预后的关系. 肿瘤药学, 2016, 6(1): 44-48.
10. Lizée G, Overwijk WW, Radvanyi L, et al. Harnessing the power of the immune system to target cancer. Annu Rev Med, 2013, 64: 71-90.
11. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med, 2015, 373(19): 1803-1813.
12. Zuo QZ, Qin WX. Progress of CTLA-4 and PD-1 signaling pathways in immunotherapy for human solid cancers. Chin Bull Life Sci, 2017, 29(8): 713-720.
13. Sun Z, Fourcade J, Pagliano O, et al. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res, 2015, 75(8): 1635-1644.
14. Pyo JS, Kang G, Kim JY. Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. Int J Biol Markers, 2017, 32(1): e68-e74.
15. Uruga H, Bozkurtlar E, Huynh TG, et al. Programmed cell death ligand (PD-L1) expression in stage Ⅱ and Ⅲ lung adenocarcinomas and nodal metastases. J Thorac Oncol, 2017, 12(3): 458-466.
16. 韩丽娟, 李汝平, 陈新峰, 等. B7 家族及其受体 PD-1 在人 NK/T 细胞淋巴瘤中的表达及临床意义. 中国肿瘤临床, 2014, 41(6): 363-367.
17. Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta, 2011, 1808(5): 1290-1308.
18. Yuan G, Jones GB. Towards next generation adenosine A(2A) receptor antagonists. Curr Med Chem, 2014, 21(34): 3918-3935.
19. Whiteside TL, Mandapathil M, Schuler P. The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem, 2011, 18(34): 5217-5223.
20. Hatfield SM, Sitkovsky M. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer. Curr Opin Pharmacol, 2016, 29: 90-96.
21. Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A, 2013, 110(36): 14711-14716.
22. Cekic C, Day YJ, Sag D, et al. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res, 2014, 74(24): 7250-7259.
23. Young A, Ngiow SF, Barkauskas DS, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell, 2016, 30(3): 391-403.
24. Beavis PA, Milenkovski N, Henderson MA, et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res, 2015, 3(5): 506-517.